InflaRx (NASDAQ:IFRX) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

InflaRx (NASDAQ:IFRX) released its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04), Zacks reports.

InflaRx Stock Up 7.0%

Shares of InflaRx stock traded up $0.12 during trading hours on Friday, hitting $1.84. The company’s stock had a trading volume of 1,167,412 shares, compared to its average volume of 890,553. The business has a fifty day moving average of $1.89 and a 200 day moving average of $1.53. InflaRx has a 1-year low of $0.78 and a 1-year high of $2.95. The company has a market capitalization of $133.01 million, a PE ratio of -3.17 and a beta of 2.48.

Institutional Trading of InflaRx

Institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC raised its position in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the period. Woodline Partners LP purchased a new stake in shares of InflaRx in the first quarter worth about $766,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of InflaRx in the second quarter worth about $262,000. Squarepoint Ops LLC grew its stake in shares of InflaRx by 29.1% in the third quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after buying an additional 42,489 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of InflaRx in the third quarter valued at about $214,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on IFRX shares. Zacks Research upgraded shares of InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Oppenheimer initiated coverage on shares of InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price for the company. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, HC Wainwright lifted their price target on shares of InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, InflaRx has an average rating of “Moderate Buy” and an average target price of $7.33.

InflaRx Company Profile

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.